Board of Directors

Xiaodong Wang, Ph.D.

Director of the National Institue of Biological Sciences in Beijing
Co-founder of BeiGene

Nan Tang, M.D., Ph.D.

Founder & Chairman

Jianhua Sui, M.D., Ph.D.

To be filled in
Nan Tang, M.D., Ph.D.
Founder & Chairman

Nan Tang, M.D., Ph.D., is the founder and chairm of pulmongene, and currently the Principal Investigator of NIBS. Dr. Nan is an internationally renowned expert in pulmonary fibrosis and alveolar regeneration and has more than 20 years’ experience in investigating molecular and cellular drivers that promote alveolar regeneration. She established the first authentic IPF mouse model and identified of novel therapeutic targets of lung diseases. Dr. Tang has co-authored 27 publications and holds 5 patents in the areas of lung diseases and alveolar regeneration, the total impact facter exceeds 390. Dr. Nan holds a Ph.D. from the University of California, San Diego, USA and subsequently did her research training in the laboratory of Dr. Gail Martin at the University of California, San Francisco, USA

Xiaodong Wang, Ph.D.
Director of the National Institue of Biological Sciences in Beijing

Co-founder of BeiGene
Xiaodong Wang, Ph.D. has been a director of the company since its inception. He is a co-founder of BeiGene and has served as Chairman of our Scientific Advisory Board since 2011. Dr. Wang is the founding Director of the National Institute of Biological Sciences in Beijing, serving since 2003, and became its Director and Investigator in 2010. He previously served as a Howard Hughes Medical Institute Investigator (1997-2010) and was the George L. MacGregor Distinguished Chair Professor in Biomedical Sciences at the University of Texas Southwestern Medical Center in Dallas, Texas (2001-2010). Dr. Wang received his Ph.D. in biochemistry from the University of Texas Southwestern Medical Center and B.S. in biology from Beijing Normal University. In 2004 Dr. Wang became a member of the U.S. National Academy of Sciences – one of the highest honors attainable by an American scientist – and has been a foreign associate of the Chinese Academy of Sciences since 2013.
Jianhua Sui, M.D., Ph.D.
none
Dr. Sui is a co-founder & Board of Director of Pulmongene. She has extensive expertise in the discovery, engineering, and development of therapeutic antibodies, and has broad research experience in Virology, Immunology, and Oncology. She developed several first-in-class antibody candidates in clinical and preclinical stages. Dr. Sui received her Ph.D. from Peking Union Medical College in 2000. Prior to co-founding Huahui Health, Dr. Sui received her Postdoc training and then served as a faculty member at Dana-Faber Cancer Institute, Harvard Medical School from 2000 to 2011. Dr. Sui joined NIBS and founded the Biologics Research Center at NIBS in 2012, and served as the Director since then.
Quanhong Yuan
none

Yuan Quanhong obtained a Bachelor’s degree in Engineering from Zhejiang University in 1996, a Master’s degree in Management from Zhejiang University in 2001, and a Master’s degree in Business Administration from China Europe International Business School in 2008. He has served in various companies including Shanghai Industrial and Pharmaceutical Joint Group Co., Ltd. (which merged with Shanghai Pharmaceutical Group Co., Ltd. in 2008), Xinneng Industrial Investment Co., Ltd., and Yiren Investment Group Co., Ltd. He led the establishment of Hankang Capital in 2010 and has been serving as the company’s management partner ever since, responsible for all fund raising and project investment decisions under Hankang Capital’s management.

Yuan Quanhong has over 20 years of investment experience in the Chinese biopharmaceutical industry and has been responsible for investing in more than 30 projects in the fields of biopharmaceuticals, medical devices, and diagnostic reagents. Dozens of these projects have grown into industry leaders, such as Beijing Nuocheng Jianhua (09969. HK), Zhongshan Kangfang Biotechnology (09926. HK), Chengdu Konoya Biotechnology (02162. HK), Shenzhen Microchip Biotechnology (688321. SH), Shanghai Heyu Biotechnology (02256. HK), Beijing Huahui Anjian, and others. He has been awarded honors such as “Founder of China’s Most Popular Emerging Fund”, “Annual Medical and Health Investor”, and “Outstanding Venture Capitalist”. Yuan Quanhong holds multiple industry positions and is a member of the Investment Professional Committee of the China Pharmaceutical Innovation Investment Promotion Association, as well as the founding director of the China Healthcare Investment 50 Forum.

滚动至顶部